EMEA-003172-PIP01-21 - paediatric investigation plan

Emactuzumab

Key facts

• Active Substance:
  Emactuzumab
• Therapeutic area:
  Oncology
• Decision number:
  P/0510/2022
• PIP number:
  EMEA-003172-PIP01-21
• Pharmaceutical form(s):
  Concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of tenosynovial giant cell tumour
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  Synox Therapeutics Limited

  E-mail: [e-mail]

  Tel: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  02/12/2022

Decision

P/0510/2022: EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a waiver for emactuzumab (EMEA-003172-PIP01-21)

AdoptedReference Number: EMA/898536/2022